Quick Answer
Janux Therapeutics, Inc. reported Stockholders Equity of $956.82 million for the year ending 2025.
- Janux Therapeutics, Inc. showed a decrease of -6.4% in Stockholders Equity from 2024 to 2025.
- This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$9.35 million | Q2 2020: -$11.81 million | Q3 2020: -$13.04 million | Q1 2021: -$16.77 million | Q2 2021: $384.80 million | Q3 2021: $376.75 million | Q1 2022: $356.08 million | Q2 2022: $343.81 million | Q3 2022: $331.51 million | Q1 2023: $311.26 million | Q2 2023: $299.47 million | Q3 2023: $348.95 million | Q1 2024: $655.76 million | Q2 2024: $657.68 million | Q3 2024: $656.10 million | Q1 2025: $1.01 billion | Q2 2025: $990.52 million | Q3 2025: $976.56 million.
- Over the full 7 years of available data (2019 to 2025), Janux Therapeutics, Inc.'s Stockholders Equity has grown by 12,144.6%.
- Historical annual values: Fiscal year 2025: $956.82 million | Fiscal year 2024: $1.02 billion | Fiscal year 2023: $344.35 million | Fiscal year 2022: $320.74 million | Fiscal year 2021: $366.33 million | Fiscal year 2020: -$14.64 million | Fiscal year 2019: -$7.94 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: